Tig3 tumor suppressor-dependent organelle redistribution and apoptosis in skin cancer cells

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Scharadin, Tiffany M ^a   Jiang, Haibing ^a   Jans, Ralph ^a   Rorke, Ellen A ^a   Eckert, Richard L ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN A; CYCLIN D1; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN E; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROCASPASE 3; PROCASPASE 9; PROTEIN BAX; PROTEIN BCL XL; PROTEIN P21; TAZAROTENE INDUCED GENE 3; TUBULIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; BAX PROTEIN, HUMAN; BCL2L1 PROTEIN, HUMAN; CASPASE 3; CASPASE 9; CYCLINE; PROTEIN BCL X; RARRES3 PROTEIN, HUMAN; RETINOIC ACID RECEPTOR;

APOPTOSIS; ARTICLE; CANCER CELL; CELL COUNT; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL ORGANELLE; CELL PROLIFERATION; CELL STRUCTURE; CELL SURVIVAL; CELLULAR DISTRIBUTION; CENTROSOME; CONTROLLED STUDY; DNA CONTENT; EPIDERMIS; HUMAN; HUMAN CELL; MICROFILAMENT; MICROTUBULE; MICROTUBULE ORGANIZING CENTER; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SKIN CANCER; SQUAMOUS CELL CARCINOMA; ACTIN FILAMENT; ADENOVIRUS; CELL CYCLE; CENTROMERE; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; METABOLISM; PATHOLOGY; SKIN TUMOR; TUMOR CELL LINE;

ACTIN CYTOSKELETON; ADENOVIRIDAE; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; CASPASE 3; CASPASE 9; CELL COUNT; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CENTROMERE; CYCLINS; GENETIC VECTORS; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MICROTUBULES; ORGANELLES; POLY(ADP-RIBOSE) POLYMERASES; RECEPTORS, RETINOIC ACID; SKIN NEOPLASMS; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS;

EID: 80051741038     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023230     Document Type: Article

References (55)

1. Ou CC, Hsu SC, Hsieh YH, Tsou WL, Chuang TC, et al. (2008) Downregulation of HER2 by RIG1 involves the PI3K/Akt pathway in ovarian cancer cells. Carcinogenesis 29: 299-306.
2. Tsai FM, Shyu RY, Jiang SY, (2007) RIG1 suppresses Ras activation and induces cellular apoptosis at the Golgi apparatus. Cell Signal 19: 989-999.
3. Tsai FM, Shyu RY, Jiang SY, (2006) RIG1 inhibits the Ras/mitogen-activated protein kinase pathway by suppressing the activation of Ras. Cell Signal 18: 349-358.
4. Jiang SY, Wu MS, Chen LM, Hung MW, Lin HE, et al. (2005) Identification and characterization of the retinoic acid response elements in the human RIG1 gene promoter. Biochem Biophys Res Commun 331: 630-639.
5. Huang SL, Shyu RY, Yeh MY, Jiang SY, (2000) Cloning and characterization of a novel retinoid-inducible gene 1(RIG1) deriving from human gastric cancer cells. Mol Cell Endocrinol 159: 15-24.
6. DiSepio D, Ghosn C, Eckert RL, Deucher A, Robinson N, et al. (1998) Identification and characterization of a retinoid-induced class II tumor suppressor/growth regulatory gene. Proc Natl Acad Sci U S A 95: 14811-14815.
7. Duvic M, Ni X, Talpur R, Herne K, Schulz C, et al. (2003) Tazarotene-induced gene 3 is suppressed in basal cell carcinomas and reversed in vivo by tazarotene application. J Invest Dermatol 121: 902-909.
8. Duvic M, Helekar B, Schulz C, Cho M, DiSepio D, et al. (2000) Expression of a retinoid-inducible tumor suppressor, Tazarotene-inducible gene-3, is decreased in psoriasis and skin cancer. Clin Cancer Res 6: 3249-3259.
9. Duvic M, Nagpal S, Asano AT, Chandraratna RA, (1997) Molecular mechanisms of tazarotene action in psoriasis. J Am Acad Dermatol 37: S18-S24.
10. Sturniolo MT, Dashti SR, Deucher A, Rorke EA, Broome AM, et al. (2003) A novel tumor suppressor protein promotes keratinocyte terminal differentiation via activation of type I transglutaminase. J Biol Chem 278: 48066-48073.
11. Sturniolo MT, Chandraratna RA, Eckert RL, (2005) A novel transglutaminase activator forms a complex with type 1 transglutaminase. Oncogene 24: 2963-2972.
12. Jans R, Sturniolo MT, Eckert RL, (2008) Localization of the TIG3 transglutaminase interaction domain and demonstration that the amino-terminal region is required for TIG3 function as a keratinocyte differentiation regulator. J Invest Dermatol 128: 517-529.
13. Rice RH, Green H, (1977) The cornified envelope of terminally differentiated human epidermal keratinocytes consists of cross-linked protein. Cell 11: 417-422.
14. Ta BM, Gallagher GT, Chakravarty R, Rice RH, (1990) Keratinocyte transglutaminase in human skin and oral mucosa: cytoplasmic localization and uncoupling of differentiation markers. J Cell Sci 95: 631-638.
15. Rice RH, Rong XH, Chakravarty R, (1990) Proteolytic release of keratinocyte transglutaminase. Biochem J 265: 351-357.
16. Chakravarty R, Rice RH, (1989) Acylation of keratinocyte transglutaminase by palmitic and myristic acids in the membrane Anchorage region. J Biol Chem 264: 625-629.
17. Rice RH, Chakravarty R, Chen J, O'Callahan W, Rubin AL, (1988) Keratinocyte transglutaminase: regulation and release. Adv Exp Med Biol 231: 51-61.
18. Candi E, Tarcsa E, Idler WW, Kartasova T, Marekov LN, et al. (1999) Transglutaminase cross-linking properties of the small proline-rich 1 family of cornified cell envelope proteins. Integration with loricrin. J Biol Chem 274: 7226-7237.
19. Steinert PM, Candi E, Tarcsa E, Marekov LN, Sette M, et al. (1999) Transglutaminase crosslinking and structural studies of the human small proline rich 3 protein. Cell Death Differ 6: 916-930.
20. Kim SY, Chung SI, Yoneda K, Steinert PM, (1995) Expression of transglutaminase 1 in human epidermis. J Invest Dermatol 104: 211-217.
21. Ogawa H, Goldsmith LA, (1976) Human epidermal transglutaminase. Preparation and properties. J Biol Chem 251: 7281-7288.
22. Eckert RL, Sturniolo MT, Broome AM, Ruse M, Rorke EA, (2005) Transglutaminase function in epidermis. J Invest Dermatol 124: 481-492.
23. Deucher A, Nagpal S, Chandraratna RA, Di Sepio D, Robinson NA, et al. (2000) The carboxy-terminal hydrophobic domain of TIG3, a class II tumor suppressor protein, is required for appropriate cellular localization and optimal biological activity. Int J Oncol 17: 1195-1203.
24. Doxsey S, Zimmerman W, Mikule K, (2005) Centrosome control of the cell cycle. Trends Cell Biol 15: 303-311.
25. Thompson HM, Cao H, Chen J, Euteneuer U, McNiven MA, (2004) Dynamin 2 binds gamma-tubulin and participates in centrosome cohesion. Nat Cell Biol 6: 335-342.
26. Lim HH, Zhang T, Surana U, (2009) Regulation of centrosome separation in yeast and vertebrates: common threads. Trends Cell Biol 19: 325-333.
27. Soldati T, Schliwa M, (2006) Powering membrane traffic in endocytosis and recycling. Nat Rev Mol Cell Biol 7: 897-908.
28. Cheong JW, Jung HI, Eom JI, Kim SJ, Jeung HK, et al. (2010) Aurora-A kinase inhibition enhances the cytosine arabinoside-induced cell death in leukemia cells through apoptosis and mitotic catastrophe. Cancer Lett 297: 171-181.
29. Thyberg J, Moskalewski S, (1999) Role of microtubules in the organization of the Golgi complex. Exp Cell Res 246: 263-279.
30. Brown WJ, Farquhar MG, (1984) The mannose-6-phosphate receptor for lysosomal enzymes is concentrated in cis Golgi cisternae. Cell 36: 295-307.
31. Uyama T, Morishita J, Jin XH, Okamoto Y, Tsuboi K, et al. (2009) The tumor suppressor gene H-Rev107 functions as a novel Ca2+-independent cytosolic phospholipase A1/2 of the thiol hydrolase type. J Lipid Res 50: 685-693.
32. Uyama T, Jin XH, Tsuboi K, Tonai T, Ueda N, (2009) Characterization of the human tumor suppressors TIG3 and HRASLS2 as phospholipid-metabolizing enzymes. Biochim Biophys Acta 1791: 1114-1124.
33. Shyu RY, Chang SC, Yu JC, Hsu SJ, Chou JM, et al. (2005) Expression and regulation of retinoid-inducible gene 1 (RIG1) in breast cancer. Anticancer Res 25: 2453-2460.
34. Higuchi E, Chandraratna RA, Hong WK, Lotan R, (2003) Induction of TIG3, a putative class II tumor suppressor gene, by retinoic acid in head and neck and lung carcinoma cells and its association with suppression of the transformed phenotype. Oncogene 22: 4627-4635.
35. Lotz K, Kellner T, Heitmann M, Nazarenko I, Noske A, et al. (2005) Suppression of the TIG3 tumor suppressor gene in human ovarian carcinomas is mediated via mitogen-activated kinase-dependent and-independent mechanisms. Int J Cancer 116: 894-902.
36. Anantharaman V, Aravind L, (2003) Evolutionary history, structural features and biochemical diversity of the NlpC/P60 superfamily of enzymes. Genome Biol 4: R11.
37. Husmann K, Sers C, Fietze E, Mincheva A, Lichter P, et al. (1998) Transcriptional and translational downregulation of H-REV107, a class II tumour suppressor gene located on human chromosome 11q11-12. Oncogene 17: 1305-1312.
38. Hajnal A, Klemenz R, Schafer R, (1994) Subtraction cloning of H-rev107, a gene specifically expressed in H-ras resistant fibroblasts. Oncogene 9: 479-490.
39. Jahng WJ, Xue L, Rando RR, (2003) Lecithin retinol acyltransferase is a founder member of a novel family of enzymes. Biochemistry 42: 12805-12812.
40. Han BG, Cho JW, Cho YD, Kim SY, Yoon HJ, et al. (2010) Expression, purification and biochemical characterization of the N-terminal regions of human TIG3 and HRASLS3 proteins. Protein Expr Purif 71: 103-107.
41. Huang SL, Shyu RY, Yeh MY, Jiang SY, (2002) The retinoid-inducible gene I: effect on apoptosis and mitogen-activated kinase signal pathways. Anticancer Res 22: 799-804.
42. Tsai FM, Shyu RY, Lin SC, Wu CC, Jiang SY, (2009) Induction of apoptosis by the retinoid inducible growth regulator RIG1 depends on the NC motif in HtTA cervical cancer cells. BMC Cell Biol 10: 15.
43. Pillai S, Bikle DD, Mancianti ML, Cline P, Hincenbergs M, (1990) Calcium regulation of growth and differentiation of normal human keratinocytes: modulation of differentiation competence by stages of growth and extracellular calcium. J Cell Physiol 143: 294-302.
44. Simmons DP, Peach ML, Friedman JR, Green MM, Nicklaus MC, et al. (2006) Evidence that sequence homologous region in LRAT-like proteins possesses anti-proliferative activity and DNA binding properties: translational implications and mechanism of action. Carcinogenesis 27: 693-707.
45. Aslan JE, Thomas G, (2009) Death by Committee: Organellar Trafficking and Communication in Apoptosis. Traffic 10: 1390-1404.
46. Ouasti S, Matarrese P, Paddon R, Khosravi-Far R, Sorice M, et al. (2007) Death receptor ligation triggers membrane scrambling between Golgi and mitochondria. Cell Death Differ 14: 453-461.
47. Matarrese P, Manganelli V, Garofalo T, Tinari A, Gambardella L, et al. (2008) Endosomal compartment contributes to the propagation of CD95/Fas-mediated signals in type II cells. Biochem J 413: 467-478.
48. Degli EM, (2008) Organelle intermixing and membrane scrambling in cell death. Methods Enzymol 442: 421-438.
49. Kim R, (2005) Recent advances in understanding the cell death pathways activated by anticancer therapy. Cancer 103: 1551-1560.
50. Degli EM, Tour J, Ouasti S, Ivanova S, Matarrese P, et al. (2009) Fas death receptor enhances endocytic membrane traffic converging into the Golgi region. Mol Biol Cell 20: 600-615.
51. Schliwa M, Woehlke G, (2003) Molecular motors. Nature 422: 759-765.
52. Sesso A, Fujiwara DT, Jaeger M, Jaeger R, Li TC, et al. (1999) Structural elements common to mitosis and apoptosis. Tissue Cell 31: 357-371.
53. Nozawa K, Fritzler MJ, Takasaki Y, Wood MR, Chan EK, (2009) Co-clustering of Golgi complex and other cytoplasmic organelles to crescentic region of half-moon nuclei during apoptosis. Cell Biol Int 33: 148-157.
54. Leist M, Jaattela M, (2001) Four deaths and a funeral: from caspases to alternative mechanisms. Nat Rev Mol Cell Biol 2: 589-598.
55. Robinson NA, LaCelle PT, Eckert RL, (1996) Involucrin is a covalently crosslinked constituent of highly purified epidermal corneocytes: evidence for a common pattern of involucrin crosslinking in vivo and in vitro. J Invest Dermatol 107: 101-107.